Statement showing un-audited Financial results for the quarter ended 30.06.2025 along with Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported revenue from operations of Rs. 1,085.36 lakhs for Q1 FY26, down from Rs. 1,188.88 lakhs in Q1 FY25, an 8.7% year-on-year decline. The company posted a loss before tax of Rs. 7.10 lakhs, marginally better than the Rs. 6.94 lakh loss a year ago. After a deferred tax credit of Rs. 2.75 lakhs, net loss came in at Rs. 4.35 lakhs versus Rs. 7.76 lakhs in Q1 FY25. Basic EPS was Rs. -0.06 versus Rs. -0.10 previously. The full-year FY25 had ended with a much larger loss of Rs. 97.87 lakhs on revenue of Rs. 5,019.52 lakhs. The statutory auditor M. A. Shah & Co. issued an unmodified limited review report with no qualifications or emphasis-of-matter paragraphs.
Despite the revenue dip, the company narrowed its quarterly loss slightly, but weak operating margins and continued losses mean the stock remains under pressure with no near-term profit visibility for shareholders.